DS Research has been involved as a clinical research site for many Takeda trials, and we’re excited to share their positive topline results from the pivotal Phase 3 LATITUDE studies of zasocitinib (TAK-279). This is a once-daily oral TYK2 inhibitor for moderate-to-severe plaque psoriasis — with over half of patients achieving nearly clear or clear skin (PASI 90) and ~30 % reaching complete clearance (PASI 100) by week 16, and a safety profile consistent with earlier data. These strong results support the potential of a new convenient oral treatment option for psoriasis and reinforce the value of clinical research partnerships like ours at DS Research in advancing meaningful therapies for patients.
The full press release is available on Takeda.com.